NO20092024L - En farmasoytisk sammensetning med antipsykotisk, antidepressiv eller antiepileptisk aktivitet med redusert bivirkning - Google Patents

En farmasoytisk sammensetning med antipsykotisk, antidepressiv eller antiepileptisk aktivitet med redusert bivirkning

Info

Publication number
NO20092024L
NO20092024L NO20092024A NO20092024A NO20092024L NO 20092024 L NO20092024 L NO 20092024L NO 20092024 A NO20092024 A NO 20092024A NO 20092024 A NO20092024 A NO 20092024A NO 20092024 L NO20092024 L NO 20092024L
Authority
NO
Norway
Prior art keywords
antidepressant
antipsychotic
pharmaceutical composition
side effect
reduced side
Prior art date
Application number
NO20092024A
Other languages
English (en)
Inventor
Kalman Takacs
Balazs Suemegi
Peter Literati Nagy
Jesse Roth
Zoltan Szilvassy
Kalman Tory
Mike Brownstein
Laszlo Vigh
Jozsef Mandl
Sandor Bernath
Attila Kolonics
Gabor Balogh
Janos Egri
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Publication of NO20092024L publication Critical patent/NO20092024L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Bivirkning som fører til overvekt eller fedme ved medikamentering med et kjent antipsykotisk middel, antidepressivt middel eller antlepileptisk middel reduseres ved administrasjon av O-(3-piperidino-2-hydroksy-l-propyl)-nikotinsyre amidoxim eller et farmasøytisk akseptabelt syreaddisjonssalt derav.
NO20092024A 2006-11-02 2009-05-25 En farmasoytisk sammensetning med antipsykotisk, antidepressiv eller antiepileptisk aktivitet med redusert bivirkning NO20092024L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85617706P 2006-11-02 2006-11-02
US11/687,954 US20080108602A1 (en) 2006-11-02 2007-03-19 Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
PCT/HU2007/000067 WO2008053257A1 (en) 2006-11-02 2007-07-23 A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect

Publications (1)

Publication Number Publication Date
NO20092024L true NO20092024L (no) 2009-06-02

Family

ID=38595981

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092024A NO20092024L (no) 2006-11-02 2009-05-25 En farmasoytisk sammensetning med antipsykotisk, antidepressiv eller antiepileptisk aktivitet med redusert bivirkning

Country Status (20)

Country Link
US (3) US20080108602A1 (no)
EP (1) EP2089032B1 (no)
JP (1) JP2010509200A (no)
KR (1) KR20090077973A (no)
AT (1) ATE491452T1 (no)
AU (1) AU2007315932A1 (no)
BR (1) BRPI0717868A2 (no)
CA (1) CA2668384A1 (no)
DE (1) DE602007011316D1 (no)
DK (1) DK2089032T3 (no)
HK (1) HK1131736A1 (no)
HR (1) HRP20110139T1 (no)
IL (1) IL198294A (no)
MX (1) MX2009004579A (no)
NO (1) NO20092024L (no)
PL (1) PL2089032T3 (no)
PT (1) PT2089032E (no)
RU (1) RU2440116C2 (no)
SI (1) SI2089032T1 (no)
WO (1) WO2008053257A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
AU2017364899B2 (en) 2016-11-28 2023-07-06 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
US20210220298A1 (en) * 2018-06-29 2021-07-22 Tufts Medical Center, Inc. Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187220A (en) * 1977-08-30 1980-02-05 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU9502843D0 (en) * 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
US6884424B2 (en) * 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
US6458371B1 (en) * 1995-12-22 2002-10-01 Medgene, Limited Cosmetic composition and a method for the prevention and/or reduction of the photoaging processes of the skin
HUP9701080A3 (en) * 1997-06-23 1999-05-28 Gene Res Lab Inc New York N Pharmaceutical composition containing a compound of antiviral activity and a hydroximic acid ester derivative
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
MXPA04000324A (es) * 2001-07-17 2004-07-23 N Gene Res Lab Inc Una combinacion farmaceutica sinergistica para la prevencion o tratamiento de diabetes.
US6831077B2 (en) * 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
HUP0401177A2 (en) * 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition for increasing the mitochondrial genesis

Also Published As

Publication number Publication date
SI2089032T1 (sl) 2011-04-29
HK1131736A1 (en) 2010-02-05
EP2089032A1 (en) 2009-08-19
WO2008053257A1 (en) 2008-05-08
JP2010509200A (ja) 2010-03-25
DE602007011316D1 (de) 2011-01-27
AU2007315932A1 (en) 2008-05-08
US20150366852A1 (en) 2015-12-24
RU2440116C2 (ru) 2012-01-20
EP2089032B1 (en) 2010-12-15
RU2009120115A (ru) 2010-12-10
IL198294A (en) 2011-09-27
US20100311719A1 (en) 2010-12-09
ATE491452T1 (de) 2011-01-15
US20080108602A1 (en) 2008-05-08
KR20090077973A (ko) 2009-07-16
MX2009004579A (es) 2009-06-05
DK2089032T3 (da) 2011-03-14
IL198294A0 (en) 2010-02-17
PL2089032T3 (pl) 2011-05-31
HRP20110139T1 (hr) 2011-04-30
BRPI0717868A2 (pt) 2013-10-29
PT2089032E (pt) 2011-03-23
CA2668384A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
IL190951A0 (en) Method of acting upon organism by targeted delivery of biologicaly active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2010084115A3 (en) Antiviral agents
EP3251674A3 (en) Antiviral azasugar-containing nucleosides
NO20092024L (no) En farmasoytisk sammensetning med antipsykotisk, antidepressiv eller antiepileptisk aktivitet med redusert bivirkning
MY148723A (en) Use of pinolenic acid for the treatment of obesity
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
EA201270800A1 (ru) С-28 амиды модифицированных производных с-3 бетулиновой кислоты в качестве ингибиторов созревания вич
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
BR112012003283A8 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
MX2010007083A (es) Combinacion anti-retroviral.
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
IL188438A (en) A heterocyclic active drug with five benzoposes, or a pharmaceutically acceptable salt and aster salts product, as well as compounds containing them and their use as @catol - o @ - @ of @ enzyme @ dead G iltransferase @@ comtI
DE602007010819D1 (de) Verringerung von übergewicht oder fettsucht
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
WO2012142575A3 (en) Monomeric trioxane amide sulfur compounds
WO2010080414A3 (en) Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents
MX2009004295A (es) Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.
WO2006133194A3 (en) Methods for treating viral infection with oral or injectible drug solution
WO2011058336A3 (en) Tablet comprising gum arabic
TW200800977A (en) A new salt
WO2008041116A3 (en) Formulations of active principles incorporated in slns suitable for transdermal administration
AU2016219606A1 (en) Pharmaceutical composition for treating or preventing burn injuries

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application